Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
US12280052B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 29, 2019 |
| Grant date | Apr 22, 2025 |
| Priority date | — |
| Expiry date | Dec 3, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P15/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides compositions and methods for treating endometrial growth disorders in a patient, such as a human patient, and particularly pre-menopausal female human patients. Exemplary disorders that may be treated using the compounds and therapeutic regimens described herein include adenomyosis and rectovaginal endometriosis. The compounds described herein that may be used to treat such indications include gonadotropin-releasing hormone (GnRH) antagonists. Suitable GnRH antagonists useful in conjunction with the compositions and methods described herein include thieno[3,4d]pyrimidine derivatives, such as 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4d]pyrimidine-5-carboxylic acid and the choline salt thereof, among others.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.